Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 10 results.
User Information
Export Records
  1. 1.   The frequency of Ras mutations in cancer
  2. Prior, Ian A; Hood, Fiona E; Hartley,Jim
  3. Cancer research. 2020, JUL 15; 80(14): 2969-2974.
  1. 2.   Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
  2. Nussinov,Ruth; Tsai,Chung-Jung; Jang,Hyunbum
  3. Seminars in Cancer Biology. 2019, FEB; 54: 114-120.
  1. 3.   Calmodulin and IQGAP1 activation of PI3K alpha and Akt in KRAS, HRAS and NRAS-driven cancers
  2. Nussinov, Ruth; Zhang, Mingzhen; Tsai, Chung-Jung; Jang, Hyunbum
  3. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE. 2018, Jun; 0925-4439:(6, Part B, Special Issue): 2304-2314.
  1. 4.   Oncogenic Ras Isoforms Signaling Specificity at the Membrane
  2. Nussinov, Ruth; Tsai, Chung-Jung; Jang, Hyunbum
  3. CANCER RESEARCH. 2018, Feb 1; 78(3): 593-602.
  1. 5.   RAS Proteins and Their Regulators in Human Disease
  2. Simanshu, Dhirendra; Nissley, Dwight; McCormick, Frank
  3. Cell. 2017, Jun 29; 170(1): 17-33.
  1. 6.   Hematopoiesis and leukemogenesis in mice expressing oncogenic Nras(G12D) from the endogenous locus
  2. Li, Q.; Haigis, K. M.; McDaniel, A.; Harding-Theobald, E.; Kogan, S. C.; Akagi, K.; Wong, J. C. Y.; Braun, B. S.; Wolff, L.; Jacks, T.; Shannon, K.
  3. Blood. 2011, Feb; 117(6): 2022-2032.
  1. 7.   Differences between the mutational consequences of replication of cis- and trans-opened benzo[a]pyrene 7,8-diol 9,10-epoxide- deoxyguanosine adducts in M13mp7L2 constructs
  2. Ponten, I.; Kroth, H.; Sayer, J. M.; Dipple, A.; Jerina, D. M.
  3. Chemical Research in Toxicology. 2001 14(6): 720-726.
  1. 8.   Hematopoietic switch from lymphoid to granulocytic development in 3LL tumor-bearing mice
  2. Lee, J. K.; Back, T. C.; Komschlies, K. L.; Ruscetti, F. W.; Young, H. A.; Wiltrout, R. H.
  3. In Vivo. 2001 15(4): 255-263.
  1. 9.   Factors determining mutagenic potential for individual cis and trans opened benzo[c]phenanthrene diol epoxide-deoxyadenosine adducts
  2. Ponten, I.; Sayer, J. M.; Pilcher, A. S.; Yagi, H.; Kumar, S.; Jerina, D. M.; Dipple, A.
  3. Biochemistry. 2000 39(14): 4136-4144.
  1. 10.   Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
  2. Zujewski, J.; Horak, I. D.; Boland, C. J.; Woestenborghs, R.; Bowden, C.; End, D. W.; Piotrovsky, V. K.; Chiao, J.; Belly, R. T.; Todd, A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F. T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.; Cowan, K. H.
  3. Journal of Clinical Oncology. 2000 18(4): 927-941.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel